{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-26-000011","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.365025+00:00","generated_at":"2026-05-15T23:20:50.699071+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novavax Q4 net income $18M, full-year profit $440M; Pfizer Matrix-M license deal","bullets":["Q4 2025 revenue $147M (+67% YoY); net income $18M vs $81M loss in Q4 2024.","Full year 2025 revenue $1.12B (+65% YoY); net income $440M vs $187M loss in 2024.","Jan 2026: non-exclusive Pfizer license for Matrix-M in two areas; $30M upfront, up to $500M milestones plus royalties.","Cash $751M at Dec 2025 (down from $938M); Feb 2026 $330M credit facility from MidCap Financial, initial $50M draw.","Cost reductions exceed goals; 2026 Non-GAAP R&D+SG&A target $310-340M, falling to ≤$200M by 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-26-000011","json":"https://secwatch.observer/filing/0001000694-26-000011.json","markdown":"https://secwatch.observer/filing/0001000694-26-000011.md","text":"https://secwatch.observer/filing/0001000694-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069426000011/0001000694-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069426000011/nvax-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:20:50.699071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}